ABO incompatible stem cell transplantation in children does not influence outcome

Area of Science:

• Pediatric Hematology
• Immunology
• Transplantation Science

Background:

• Delayed engraftment and hemolysis are known complications of ABO incompatible hematopoietic stem cell transplantation (HSCT).
• Limited data exists on the long-term clinical outcomes of ABO incompatibility in pediatric HSCT patients.

Purpose of the Study:

• To evaluate the influence of ABO donor/recipient incompatibility on the long-term clinical outcome of pediatric allogeneic stem cell transplantation.
• To analyze survival, graft-versus-host disease (GvHD), relapse rates, infection rates, and hospital stay duration in relation to ABO compatibility.

Main Methods:

• Retrospective analysis of 216 children undergoing allogeneic HSCT between 1992 and 2003.
• Outcomes were assessed based on donor type, including ABO compatibility status (compatible, major, minor, bi-directional incompatible).
• Statistical analysis was performed to determine the influence of ABO incompatibility on various clinical outcomes.

Main Results:

• ABO incompatibility did not significantly affect survival rates (P=0.3762), GvHD incidence (P=0.253), or relapse rates (P=0.930).
• Leukocyte recovery was influenced by ABO incompatibility (P=0.0493).
• Infection rates, transfusion requirements, and hospital stay duration were not significantly impacted by ABO incompatibility.

Conclusions:

• In pediatric HSCT, ABO major and/or minor mismatch does not significantly influence patient outcomes.
• Donor selection for pediatric HSCT should prioritize HLA matching and CMV status over ABO blood group compatibility.
• These findings support prioritizing HLA and CMV status in donor selection for pediatric HSCT.